Retrasib reported non consolidated earnings results for the year 2014. The company announced that it turned to a non-consolidated net loss of RON 5.980 million ($1.515 million/EUR 1.349 million) in 2014 from a net profit of RON 2.080 million a year earlier. Operating loss was RON 4.601 million in 2014, as compared to an operating profit of RON 4.146 million a year ago.

Pre-tax loss amounted to RON 5.980 million versus a pre-tax profit of RON 2.408 million in 2013. The company's total revenue fell to RON 34.807 million from RON 44.039 million in 2013.